COVID-19 Research
The Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the COVID-19 respiratory disease. SARS-CoV-2 is highly contagious and transmits predominantly via the respiratory route. It is an enveloped virus with a single-stranded RNA genome. Small molecules can be used to investigate the virus and the corresponding immune response. Researchers can save up to 50% on high purity Covid-19 research products - they are up to half the price of other suppliers.
View products: Compound repurposing | Virus attachment / entry | Viral replication | Cytokine storm | Organoids | Cell culture reagents | Cell stains, viability & proliferation | CRISPR / gene editing
CAT335 (HB8146)
Description:K2P2.1 (TREK-1) modulator. Selectively and irreversibly activates TREK-1CG* but not wild-type K2P2.1 (TREK-1)
Purity:>98%
-
Clozapine (HB1607)
Description:Prototypic, atypical antipsychotic, binds to both serotonin and dopamine receptors
Purity:>99%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
-
Clozapine N-oxide (CNO) (freebase) (HB1807)
Description:Prototypical DREADD activator. Clozapine metabolite.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
-
Deschloroclozapine (DCZ) (HB8555)
Description:Potent, selective and metabolically stable hM3Dq and hM4Di muscarinic DREADD actuator.
Purity:>98%
- Description:
Potent, selective and metabolically stable hM3Dq and hM4Di muscarinic DREADD actuator. Water soluble.
Purity:>99%
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant. Water soluble.
Purity:>98%
-
DREADD agonist 21 (Compound 21) (HB4888)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant.
Purity:>98%
-
Iperoxo (HB9785)
Description:Potent muscarinic acetylcholine receptor superagonist. Also binds the hM3R-miniGq receptor.
